Unveiling 18 Analyst Insights On Blueprint Medicines
Unveiling 18 Analyst Insights On Blueprint Medicines
公佈18位分析師對藍圖藥物的見解
Ratings for Blueprint Medicines (NASDAQ:BPMC) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去三個月中，18位分析師提供了Blueprint Medicines（納斯達克股票代碼：BPMC）的評級，顯示了看漲和看跌的觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他們最近的評級，簡要介紹了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $111.06, a high estimate of $168.00, and a low estimate of $65.00. Surpassing the previous average price target of $89.40, the current average has increased by 24.23%.
在對12個月目標股價的評估中，分析師公佈了對藍圖藥品的見解，將平均目標價定爲111.06美元，最高估計爲168.00美元，低估值爲65.00美元。超過了之前的平均目標股價89.40美元，目前的平均價格上漲了24.23％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析師評級：深度分析
The analysis of recent analyst...
對分析師近...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。